Literature DB >> 34048184

TERT Genotype Polymorphism: A Glance of Change Egyptian MDS Outcomes.

Nadia El Menshawy1, Shaimaa El-Ashwah2, Mohamed A Ebrahim3, Metwally Ibrahem Mortada1, Ahmed Ramez3, Doaa M Attia1.   

Abstract

BACKGROUND: Myelodysplastic Syndromes (MDS)are clonal hematologic disorders characterized by genetic instability and ineffective hematopoiesis associated with telomere dysfunction. We aimed at investigating the association between the rs2242652 single nucleotide variant of the TERT gene and susceptibility for MDS, as well as its prognostic impact and relation to disease phenotype.
METHODS: Genotyping analysis was carried on 100 MDS patients recruited at Mansoura Oncology center, in addition to 100 healthy subjects for detection of rs2242652 variant of TERT gene on chromosome 5 by real time PCR following the protocol of Custom TaqMan® SNP Genotyping.
RESULTS: The rs2242652 TERT genetic polymorphism was associated with an increased risk of MDS (odds ratios 2.6 for genotype GA, 6.4 for genotype AA). The majority of AA homozygous mutant variant were associated pancytopenia (88%), poor risk cytogenetics (92%) and High/very high IPSS-R score (88%). At the end of follow-up (median 30 months), 14% of the cases transformed to secondary AML. The rate of leukemic transformation was significantly associated with the mutant AA genotype (93% of transformed cases, 52% of AA genotype cases; p < 0.0001). Survival outcome was inferior in AA mutant genotype (median 14 months, 95% CI: 12-16 months) to the GA genotype (median 30 months, 95% CI: 26-33 months) and those of the GG genotype (median not reached), p.

Entities:  

Keywords:  Myelodysplatic Syndromes; SNVs; rs2242652TERT

Year:  2021        PMID: 34048184     DOI: 10.31557/APJCP.2021.22.5.1547

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  1 in total

1.  Lymphocyte Activation Gene 3 Single-Nucleotide Polymorphisms in Bone Marrow Failure Diseases.

Authors:  Yingying Sun; Qiuying Cao; Xiaoyu Zhao; Chunyan Liu; Zonghong Shao
Journal:  Anal Cell Pathol (Amst)       Date:  2022-02-27       Impact factor: 2.916

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.